
Used to move water (with impurities) from one container to another, now @MenloVentures.
Joined July 2009
- Tweets49
- Following662
- Followers314
- Likes117
Number of new drugs being tested with PD-(L)1? >800.
> 12 monoclonal antibodies against CTLA-4
> 79 ADCs
> 367 named targets, but only about 51 drugs chasing a novel target alone
Yes lots of crowding but at least some willing to stake out new ground.
Full list, most common targets, modalities, and cancer types: browniandrift.com/posts/pd1/…
27
"Pharma will never pay for AI tools."
> $700M this year and growing as projects moves from pilots to scaled deployments
Those tools are already having real impact on drug programs today with expectations of greater acceleration in the years to come.
Healthcare is now AI’s biggest vertical market.
Spend grew 2.5x to $3.7B this year, more than double legal ($1.8B) and more than legal and finance combined.
It started in paperwork: scribing and billing. Now it’s moving into drug discovery, patient engagement and clinical decision support. Clinical copilots alone grew 5.5x to $550M.
Our 2026 State of AI in Healthcare report from @grgyap, @jpsanday, @CroomBeatty, @hu_j, @derekgxiao and @sabrinarlu: mnlo.vc/2026-healthcare-ai-r…
What's uncaptured is how much of the stipend goes to housing costs and how much each university subsidizes (or not) their housing / what availability there is. Harvard explicitly uses prevailing market rates vs Stanford which has both a higher stipend ($58k) and offers housing below local rates--which, yeah, bay area housing.
Harvard PhD students are on strike, postdocs and lecturers will probably join next week.
Harvard PhD students obviously enjoy great privilege, but this privilege is not reflected in our wages.
Here is a comparison to my "alma mater". There is room to move.
2
340
Healthcare and pharma lowkey leading enterprise AI adoption.
This just in: Menlo Ventures’ 2026 The State of Enterprise AI report is live.
In 2026, enterprise AI spend skyrocketed 5.4x from $33B to $177B in a single year.
The full report covers how AI became an economy-scale force this year, and shows where the dollars are going, which markets are working, and which models buyers choose.
More from @timt, @mejoff, @deedydas, and @derekgxiao: mnlo.vc/enterprise-ai-26
Was wondering what @deedydas signals would look like for biotech startups.
What attributes correlated with attracting either a top specialist fund or generalist fund lead and how is it different between the two fund types?
Which startups are most likely to get an investment from top tier VCs?
I looked at ~60 attributes across 5000 startups and these were the 15 strongest.
#1 is being from a top tier fund. MBA is a negative signal
Full list of signals below:
Generalist funds much more focused on the technology/platform:
> Many founders are ex-big tech (ex-AI labs are still small numbers but that will grow)
> Computational backgrounds now flip positive
> Prone to partnering up with the academic labs where these technologies are developed
All advanced degrees now slightly negative similar to the larger set of startups.
Tend to back teams rather than solo founders.
1
116
Crowding on targets seems like a capital allocation issue rather than an AI issue. Yes it'll happen but plenty of companies working on new targets both because the molecular generation is being deployed for hard targets and AI is being used to help generate new ideas.
The Fruits of AI Drug Abundance: Indigestion In The Near Term
While the long term impact of AI is likely transformational, in the near term more drugs against known targets will likely exacerbate the crowding challenge dragging down industry R&D productivity
lifescivc.com/2026/10/the-fr…
7
363
Love reading about these projects that would have taken entire PhDs to do previously. We're going to see a lot more elegant, self-contained solutions like this in the coming months...
What will drug discovery look like when intelligence is abundant?
Our team at @generate_biomed began with this question, and we’re excited to share some results!
We took on in vivo CAR-T and designed a scaffold 70% smaller than ones in the clinic, with 3x the potency 🧵
Johnny Hu retweeted
Congratulations to Xaira Therapeutics on the successful launch of its innovative biotech which leverages AI to better understand biological systems and develop new therapeutic approaches.
We're entering an era of tremendous innovation and progress in the biotech space, and we're thrilled to partner with Xaira via @grgyap and @hu_j.
endpts.com/in-biggest-ever-b…
Johnny Hu retweeted
Liu lab #xCas9 plasmids are finally available @Addgene - and that means my blog post about them is too! Thanks @hu_j and @TyFordFever for help with editing! #CRISPR hubs.ly/H0bvgry0
Johnny Hu retweeted
Evolved Cas9 variants with broad PAM compatibility and high DNA specificity fal.cn/4smf via @nature #CRISPR
xCas9 is the flavor of the week. Excited to see what's next on the docket. #cas9 #geneediting xitter.gq/NewsfromScience/status…
From telescopes to caterpillars, this week's top stories in science: scim.ag/2CU30Wb
Johnny Hu retweeted
Researchers have evolved new variants of #CRISPR-Cas9 that are compatible with a wider range of required bases, opening access to more regions of the genome fal.cn/4i_t
Our xCas9 work was just highlighted by Nature Biotech. We evolved broader PAM compatibility and higher specificity in one protein. xitter.gq/NatureBiotech/status/9…
Genome editing: new Cas9 variants recognize a very broad range of PAM sequences and exceeds wt spCas9 in specificity go.nature.com/2HVWylc #NBThighlight

















